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Background: The purpose of this study was to develop a cost-effective approach for the determination of EGFR
and KRAS mutations in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and colorectal
cancer (CRC) samples from Chinese patients based on a sensitive pyrosequencing (PS) technique.
Methods: The NSCLC and CRC cell lines were tested to determine the limitation of detection and reproducibility of
the PS method. In addition, 494 NSCLC and 1099 CRC patient samples were assayed by PS to evaluate the EGFR or
KRAS mutation patterns according to the clinicopathological features.
Results: The PS assay was able to reproducibly detect as few as 2 % mutant alleles with excellent linearity. EGFR
mutations were detected in 35.63 % of the NSCLC samples, and KRAS mutations were detected in 39.76 % of the
CRC samples. EGFR mutations were more frequently observed to be significant by multivariate analysis in NSCLC
patients who were 65 years old or younger (OR = 2.51), had a nonsmoking history (OR = 3.63), and adenocarcinoma
(OR = 3.57), but not in females (OR = 0.64). KRAS mutations were more frequently detected in CRC patients who
were female (OR = 1.64) and 50 years old or older (OR = 4.17), and had adenocarcinoma (OR = 2.41).
Conclusions: This is the first extensive validation of PS on FFPE samples using the detection of EGFR exons 18–21
mutations and KRAS exon 2 mutations. Our results demonstrate the utility of PS analysis for the detection of
somatic EGFR and KRAS mutations in clinical samples and provide important clinical and molecular characteristics
of NSCLC and CRC from Chinese patients.
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Non-small cell lung cancer (NSCLC) and metastatic
colorectal cancer (mCRC) are the most common cancers
and the leading causes of cancer mortality [1]. Among
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Therefore, the development of novel and effective therapy
has been and continues to be imperative for public health.
In the past decade, molecularly targeted therapeutics has
been developed for the treatment of advanced NSCLC
and mCRC. Some small molecule tyrosine kinase inhibi-
tors (TKIs) and anti-epidermal growth factor receptor
(EGFR) monoclonal antibodies (mAbs) have been shown
to be effective both in preclinical and clinical trials. TKIs
targeting a mutant EGFR and mAbs binding to the
extracellular domain of EGFR have shown significant
benefit in the clinic, but their efficacy depends on the
mutations of EGFR in the tyrosine kinase region ande distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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homolog (KRAS) in the EGFR signaling pathway, re-
spectively, which have become established predictive
markers for the stratification of NSCLC and mCRC pa-
tients for targeted treatment [2, 3]. Accordingly, the US
Federal Drug Administration has approved several TKIs
and mAbs as anti-EGFR treatment for advanced NSCLC
patients with the EGFR-activating mutation and for
mCRC patients with wild-type KRAS, but not for NSCLC
patients with wild-type EGFR or CRC patients with mu-
tant KRAS [4, 5]. Thus, accurate incidence rates of EGFR
and KRAS mutations are critical to reckon the effective-
ness of molecular-targeted agents as personalized treat-
ment for advanced NSCLC and mCRC patients in any
given population.
During the past decade, the incidences of the EGFR
mutation in NSCLC patients and the KRAS mutation in
CRC patients have been shown to vary across different
ethnicities. The mutation rate of EGFR in NSCLC patients
is 16–18 % in North Americans and Europeans [6, 7],
19 % in African-Americans [8], 22 % in Indians [9], 29 %
in Koreans [10], and 40 % in Japanese [11]; for the KRAS
mutation in CRC patients, the rate is 37–54 % in North
Americans and Europeans, 47 % in African-Americans
[12], 24 % in Indians [13], 27 % in Koreans [12], and 38 %
in Japanese [14], as summarized in Additional file 1: Table
S1. However, data regarding the frequencies of EGFR and
KRAS mutations in a Chinese population currently re-
main contradictory and confusing. The currently available
data show that the frequency of NSCLC EGFR mutations
in patients from mainland China varies from 19 to 56 %
[9, 15–17], and the KRAS mutation rate in Chinese pa-
tients with CRC is 20–62 % [18–20]. Moreover, the in-
cidence of EGFR and KRAS mutations might be
underestimated or overestimated because of clinically
selected cases and the small sample sizes in those stud-
ies. Thus, it is of high importance to accurately deter-
mine the mutation rates of EGFR in NSCLC and KRAS
in CRC with a large cohort of patients.
In addition, with the advent of personalized medicine,
there is an urgent need for routine methods for rapid
and accurate detection of changes of nucleic acid in clin-
ical specimens. A wide range of techniques exist for mu-
tation detection, of which dideoxy sequencing has been
the gold standard [21]. However, the limited sensitivity
and long turnaround time of these available methods
have prompted the development of alternative techniques
for routine clinical testing that have greater diagnostic
practicality [21, 22]. Pyrosequencing is one of the latest
methods that uses luminometric instead of electrophoretic
detection [23]. This technique enables characterization of
mutations and quantification with high accuracy of mu-
tated alleles in samples with a low tumor cell density.
Pyrosequencing is particularly suitable for the targetedsequencing of short DNA fragments amplified from
older and less optimal tissue samples [24]. Owing to its
high sensitivity, pyrosequencing seems to present a
more reliable approach, allowing rapid, accurate, and
high-throughput detection of a minimal fraction of mu-
tated cells in archived clinical tumor tissue [25].
In this study, we designed an accurate and reliable py-
rosequencing assay to determine the EGFR mutation in
494 NSCLC patients and the KRAS mutation in 1099
CRC patients of Chinese ethnicity. We further retro-
spectively analyzed and correlated the EGFR and KRAS
mutations across different variables including age, gen-
der, smoking status, and histology groups.Materials and methods
Cell lines and known mutated formalin-fixed
paraffin-embedded (FFPE) tissues
Six human NSCLC and CRC cell lines (Additional file 1:
Table S2) and four known EGFR and KRAS mutation-
positive FFPE tumor tissues (Additional file 1: Table S3)
were initially used to validate the accuracy of the estab-
lished pyrosequencing method. All the cell lines were
purchased from the Cell Bank of the Chinese Academy
of Sciences (Shanghai, China). The four known mutation-
positive FFPE tissues with an expected mutation profile
based on previous Sanger sequencing analysis were histo-
logically confirmed to be tumor cells according to the
hematoxylin-eosin-stained slides.Collection of patient samples
NSCLC FFPE tissue specimens (n = 494) and CRC FFPE
tissue specimens (n = 1099) were collected from the
Department of Pathology of Xinhua Hospital affiliated
to Shanghai Jiao Tong University School of Medicine
(Shanghai, China) between January 2009 and December
2012. Written informed consent was obtained from all
patients, and the study was approved by the Ethics
Committee of Xinhua Hospital. Patient and tumor charac-
teristics, such as age, gender, smoking status, histology
and tumor sample type, are summarized in Table 1.
The material available for all tumors was tissue blocks.
Before DNA extraction, representative sections were
stained with haematoxylin and eosin (H&E) and tumors
were reviewed by two pathologists (LS and MY) and his-
tologically classified according to the 2004 WHO criteria.
Moreover, the percentages of tumor cells and extracellular
mucin, if there was a relevant amount (more than 50 % of
the tumor), or lymphocyte inflammation (more than 10 %
of lymphocytes at 20 ×magnification) were assessed.
Macrodissection was performed to guarantee at least 30 %
tumor in all cases in which there was sufficient material
available for analysis.
Table 1 Patient characteristics
Variable Number (%) Variable Number (%)
NSCLC 494 (100) CRC 1099 (100)
Age (years) Age (years)
Mean 64.70 Mean 60.95
Range 38–85 Range 36–82
Gender Gender
Male 334 (67.61) Male 657 (59.78)
Female 160 (32.39) Female 442 (40.22)
Smoking history Sublocalization
Ever smoker 348 (70.45) Proximal colon 373 (33.94)
Never smoker 146 (29.55) Distal colon 355 (32.30)
Pathological stage Rectum 371 (33.76)
I 96 (19.43) Dukes’ stage
II 75 (15.18) A 97 (8.83)
III 132 (26.72) B 517 (47.04)
IV 185 (37.45) C 343 (31.21)
Unknown 6 (1.21) D 142 (12.28)
Pathology Pathology
ADC 310 (62.75) ADC 1045 (95.09)
SCC 172 (34.82) SCC 21 (1.91)
LCC 6 (1.21) ASC 9 (0.82)
ASC 4 (0.81) UDC 18 (1.64)
Others 2 (0.40) Others 6 (0.55)
Differentiation Differentiation
Poor 97 (19.64) Poor 256 (23.29)
Moderate 249 (50.40) Moderate 752 (68.43)
Well 145 (29.35) Well 78 (7.10)
Unknown 3 (0.61) Unknown 13 (1.18)
NSCLC non-small cell lung cancer, CRC colorectal cancer, ADC adenocarcinoma,
SCC squamous cell carcinoma, LCC large cell carcinoma, ASC adenosquamous
carcinoma, UDC undifferentiated carcinoma
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The genomic DNA of the human cell lines was extracted
using the QIAamp DNA Mini Kit (Qiagen, Germany).
The genomic DNA of the FFPE samples was extracted
using the GTpure™ FFPE Tissue Kit (GeneTech, China).
All of the extracted DNA samples were quantitated with
NanoDrop spectrophotometer 2000c (Thermo Fisher,
USA) and stored at −20 °C until use.
Cell-mixing studies
To analyze the assay linearity and sensitivity, we per-
formed reconstruction experiments with the NSCLC cell
lines and CRC cell lines. The NSCLC or CRC cell lines
harboring heterozygous or homozygous mutations were
serially diluted with the corresponding wild-type cells.
The proportions of the mutant cell lines were adjusted
to 100 %, 50 %, 30 %, 20 %, 10 %, 5 %, 3 %, 2 %, and 0 %(mutant-type:wild-type), respectively. The genomic DNA
extracted from each dilution was subjected to subse-
quent pyrosequencing and dideoxy sequencing on three
separate, consecutive days. The actual percentage of the
mutant allele was determined by pyrosequencing data
from undiluted tumor cell DNA. For each tumor cell di-
lution, a theoretical percentage of the mutant allele was
then calculated.
Mutation analysis by pyrosequencing and direct dideoxy
sequencing
The polymerase chain reaction (PCR) and pyrosequenc-
ing primers are listed in Additional file 1: Table S4. The
PCR amplicons for pyrosequencing were bound to
Streptavidin-Sepharose HP (GE Healthcare, USA), puri-
fied, washed, denatured with 0.2 M NaOH, and washed
again. The pyrosequencing primer (0.3 μM) was annealed
to the purified single-stranded PCR product, the pyrose-
quencing assay was performed on a PyroMark Q24 system
(Qiagen, Germany), following the manufacturer’s instruc-
tions. The dispensation order for EGFR exons 18, 19, 20,
and 21 was GCAAGTGCTGATGCTCGT, ACGAATAC
GACGACGCTAACAGTCTACGA, GACTAGCAGCTG
CATGCT, and TGCGTGTCAACTACG, respectively. The
dispensation order for the KRAS was TACGACTCA
GATCGTAG. Our dispensation order was longer than that
found in the commercial kit; additional bases were intro-
duced in strategic positions, according to possible expected
mutated sequences (Additional file 1: Figure S1). The
amplicons for direct Sanger sequencing were analyzed and
purified with the GTpure™ Gel/PCR Extraction Kit
(GeneTech), and sequenced on an ABI 310 genetic
analyzer (Applied Biosystems).
Statistical analysis
All statistical analyses were performed using SAS ver.
9.2 (SAS Institute, Cary, NC). For continuous variables,
the median and range were calculated. A χ2 test was per-
formed in a univariate analysis in order to investigate the
relationship between the EGFR or KRAS gene mutation
rate and patient background factors. Based on the results,
multivariate logistic regression was performed, and the
odds ratio (OR) and 95 % confidence interval (95 % CI)
were calculated. Statistical significance was set at p < 0.05.
Results
Pyrosequencing with novel nucleotide dispensation order
accurately detects EGFR or KRAS mutations both in
cultured cells and FFPE tissues
The established pyrosequencing method was able to dis-
criminate the wild-type from the different mutations
presented in the mutant cell lines. As seen in the pyrose-
quencing traces of the targeted sequence of the six cell
lines, the NSCLC cell lines H1650 (c.2235_2249del15,
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specific peak patterns, which were readily distinguishable
from that of the EGFR exons 19 and 21 wild-type NSCLC
cell line A549 (Fig. 1ai and ii). Similarly, the A549 (KRAS
exon 2 c.34G>A, Fig. 1bii) and the CRC cell lines SW480
(KRAS exon 2 c.35G>T, Fig. 1biii) and DLD-1 (KRAS
exon 2 c.38G>A, Fig. 1biiii) showed specific pyrogram
traces, which were readily distinguishable from that of the
KRAS exon 2 wild-type CRC cell line HT-29 (Fig. 1bi).
The designed pyrosequencing assay was further tested
with the known mutant NSCLC- and CRC-FFPE tissues
(Additional file 1: Table S3). The two types of NSCLC-
FFPE tissues harboring different EGFR TK domain muta-
tions (Fig. 1ci and ii) and the two types of CRC-FFPE
tissues with known KRAS exon 2 mutations (Fig. 1ciii
and iiii) were detected by the established pyrosequencing
analysis, respectively. Dideoxy sequencing confirmed the
results of the pyrosequencing traces.Pyrosequencing with novel nucleotide dispensation order
demonstrates high sensitivity and excellent linearity and
reproducibility in detecting EGFR and KRAS mutations
Assay sensitivity of the pyrogram profile in discriminat-
ing different percentages of mutated alleles was initially
evaluated by using serial dilutions of mutated DNA, de-
rived from a cultured cell line with a known EGFR or
KRAS mutation, and variably mixed with wild-type
DNA obtained from a wild-type cell line. We tested
100 %, 50 %, 30 %, 20 %, 10 %, 5 %, 3 %, 2 %, and 0 %
(mutant-type/wild-type) dilutions of H1650, H1975,
SW480, and DLD-1cell lines (Fig. 2a). Our results dem-
onstrated that this method could detect at least 2 % of
the mutated alleles in the heterozygous mutant EGFR
c.2235_2249del15 (Fig. 2ai) and homozygous mutant
KRAS c.35G>T (Fig. 2aiii), 3 % of the mutated alleles in
the heterozygous mutant EGFR c.2573T>G dilution
(Fig. 2aii), and 5 % of the mutated alleles in the hetero-
zygous mutant KRAS c.38G>A dilution (Fig. 2aiiii).
Compared with the dideoxy sequencing tracings from
the amplifications on day 1, a small mutant peak was
visible in the dideoxy sequencing tracings of the 15–20 %
homozygous to 20–30 % heterozygous mutant dilutions
(Additional file 1: Figures S2–S5).
For linearity testing, based on the data generated from
the separate NSCLC or CRC cell mixing analyses, a lin-
ear relationship between the actual and theoretical per-
centages of the mutant allele was identified (Fig. 2b,
Additional file 1: Tables S5-S6). The coefficient of correl-
ation (r) was 0.99 for EGFR exon 19 c.2235_2249del15
(G>A) (Fig. 2bi), KRAS exon 2 c.35G>T (Fig. 2biii), and
KRAS exon 2 c.38G>A (Fig. 2biiii); the r value was 0.96
for EGFR exon 21 c.2573 T>G (Fig. 2bii), indicating an
excellent linearity and reproducibility.Pyrosequencing analysis results of EGFR mutations in
exons 18–21 in 494 NSCLC clinical samples
After standardization and validation by direct DNA
sequencing for the robustness, linearity, and sensitivity
of our designed pyrosequencing method, we applied it
as a routine clinical test for common EGFR mutation
assay in 494 patients diagnosed with NSCLC (Table 1).
Overall, 35.63 % (176/494) of the NSCLC samples
were identified to have EGFR TK domain mutations,
representing 16 different nucleotide mutation types
(Additional file 1: Figure S6). A total of 18.83 % (93/
494) of the mutations were located in exon 19, and
16.80 % (83/494) were located in exon 21. A total of
52.27 % (92/176) were small in-frame deletions in exon
19, while 47.16 % (83/176) were missense mutations in
exon 21. The most common mutation in exon 19 was
delE746-A750 (56.99 %, 53/93). In exon 21, the most
common mutation was located on L848R (97.59 %, 81/83).
One rare exon 19 missense mutation (c.2239 TT>CC,
p.L747P) was detected. EGFR exon 18 and exon 20
mutations were not detected in this cohort of NSCLC
samples (Table 2).EGFR mutations and clinicopathological features of NSCLS
patients
Using univariate analysis, when all histologies were ana-
lyzed together, females showed a significantly higher
frequency of the EGFR mutation compared with males
(42.50 % vs. 32.34 %, p = 0.028). Within the different
age groups, the mutation rate was significantly higher
in those 65 years old or younger than in those older
than 65 years old (45.02 % vs. 24.22 %, p < 0.001). Those
with ADC showed higher mutations than any other
histology (45.48 % vs. 19.02 %, p < 0.001). When the
ADC subgroup was analyzed by gender, the mutation
rate was predominantly higher among females com-
pared to males (56.12 % vs. 40.57 %, p = 0.011). In
addition, the smoking status was closely associated with
the EGFR mutation rate, and the mutation rate was
higher in the never-smoker group than in the smoker
group (50.68 % vs. 29.31 %, p < 0.001 (Table 3). How-
ever, there was no difference in the EGFR mutation rate
between males and females in the never-smoker group
(52.38 % vs. 50.40 %, p = 0.867). Similarly, no significant
correlation of EGFR mutations between the never-
smoker male or female ADC patients (60.00 % vs.
65.38 %, p = 0.69) was observed. When sex, age, histo-
type, and smoking history were tested by multivariate
analysis against the presence of EGFR mutations as a
dependent variable, only the female data did not remain
significant. No significant associations between EGFR
mutations and differentiation status or tumor stage
were observed (Table 3).
Fig. 1 (See legend on next page.)
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Fig. 1 Validation of the established pyrosequencing analysis method using a novel dispensation order on cell lines and FFPE tissues. DNA from
six tumor cell lines and four FFPE tissues was analyzed in parallel by pyrosequencing and dideoxy sequencing. a Examples of pyrograms obtained
on the NSCLC cell lines A549 (i and ii), H1650 (iii), and H1975 (iiii) for mutational analysis of EGFR exon 19 or exon 21. b Examples of pyrograms
obtained on the CRC cell lines HT-29 (i), SW480 (iii), and DLD-1 (iiii) as well as the NSCLC cell line A549 (ii) for mutational analysis of KRAS exon 2,
codons 12 and 13. c To test the suitability of pyrosequencing for clinical samples, the assay was used to analyze EGFR or KRAS mutations in the
following known mutated FFPE tissues: NSCLC M1 (i), NSCLC M2 (ii), CRC M1 (iii), and CRC M2 (iiii). All of the targeted mutations occurring in the
cell lines and FFPE tumor tissues could easily be distinguished by pyrosequencing. The results for the six cell lines and four FFPE tissues were
100 % concordant between the established pyrosequencing and dideoxy sequencing methods. The target nucleotide sequences are labeled and
underlined. The horizontal axis of each pyrogram, from left to right, indicates the order of reagent addition. E represents enzyme. S represents
substrate. Mutation points are indicated by light shading. The vertical axis represents the luminescence intensity, of which the peak heights are
proportional to the number of each nucleotide incorporated at one time. Sites of variation are indicated by arrows. Data are representative of five
independent analyses of the same sample
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exon 2 in 1099 CRC clinical samples
In 1099 Chinese CRC-FFPE samples (Table 1), a total of
437 missense mutations were detected at KRAS codons
12 and 13 (39.76 %, 437/1099). Nine types of KRAS exon
2 hotspot mutations were observed (Additional file 1:
Figure S7). The mutation frequencies of exon 2, codon
12 and codon 13 were 30.30 % (333/1099) and 9.46 %
(104/1099), respectively. The frequently observed muta-
tions were G>A transition (300/437, 67.65 %), followed
by G>T transversion (113/437, 25.86 %), and G>C trans-
version (24/437, 5.49 %). Furthermore, 76.20 % (333/437)
of the mutations were located in codon 12, in which the
base substitutions were mainly located at the first and sec-
ond nucleotides. The screening results also showed that
six CRC patients harbored codon 12 double G>A transi-
tions (c.34G>A and c.35G>A, 1.37 %, 6/437). Meanwhile,
104 patients had detectable mutations at codon 13
(23.80 %, 104/437), and the G>A transition at the second
nucleotide was the most frequent mutant type (c.38G>A,
96.15 %, 100/104) (Table 2).
KRAS mutations and clinicopathological features of CRC
patients
By univariate analysis, correlation of the KRAS mutation
with clinicopathological data indicated that KRAS muta-
tions were higher in females than in males (46.15 % vs.
35.46 %, p < 0.01) (Table 4). Interestingly, KRAS mutations
were significantly higher in patients who were older than
50 years old in comparison with patients younger than
50 years old (45.67 % vs. 17.67 %, p < 0.001), indicating
that KRAS mutations are uncommon in younger CRC pa-
tients. Moreover, KRAS mutations were more prevalent in
ADC patients when compared to non-ADC patients such
as those with SCC, ASC, and UDC (40.86 % vs. 18.52 %,
p = 0.002). However, KRAS mutations were not found to
be significantly associated with moderately/poorly differ-
entiated tumors in comparison with well-differentiated tu-
mors. The logistic multivariate analysis results were in line
with the univariate analysis results. No significant associ-
ation between KRAS mutations and tumor sublocalizationor the Dukes’ stage was observed in these CRC patients
(Table 4).
Discussion
In the present study, we established a practical and reli-
able pyrosequencing assay using novel nucleotide dis-
pensation order for the detection of EGFR and KRAS
mutations in a large cohort of Chinese NSCLC and CRC
patients. We further retrospectively analyzed the actual
incidence of genetic abnormalities of EGFR and KRAS
and their distribution according to clinicopathological
features in Chinese patients.
In our analysis of 494 NSCLC cases, the EGFR muta-
tion rate was 35.63 % in the Chinese population, which
was significantly higher than the EGFR mutation rates
reported in western countries, but was similar to that of
other Eastern populations (Additional file 1: Table S1).
We found a higher rate of the EGFR mutation in ADC
patients than in all patients (45.48 % vs. 35.63 %) and
among females compared to males (42.50 % vs. 32.34 %),
similar to rates in Indian, Korean, and Japanese patients
[10, 11, 26]. Although the mutation rate varies signifi-
cantly between ever smokers and never smokers across
different ethnicities, EGFR mutations have been consist-
ently reported to be more common in never smokers as
compared to ever smokers [9–11, 16, 27]. Consistently,
we found that the mutation rates of EGFR for ever
smokers and never smokers were 50.68–29.31 %, respect-
ively. Histopathologically, the mutation rates among fe-
males with ADC were predominantly higher than in males
with ADC (56.12 % vs. 40.57 %), consistent with previous
studies [28, 29]. However, no significant differences were
observed between never-smoker ADC males and females,
indicating that the lack of a gender bias among never
smokers was possibly due to the fact that there was a
lower proportion of nonsmoking males (21 nonsmokers
out of 334 males) than nonsmoking females (125 non-
smokers out of 160 females) in this study. These findings
are also consistent with similar studies on females of other
Asian ethnicities who never smoked, wherein the EGFR
mutation rate varies with the clinical stage of the female
Fig. 2 (See legend on next page.)
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Fig. 2 Limit of detection and assay linearity. Mixtures of DNA from EGFR or KRAS cell lines were analyzed in triplicate and in parallel by pyrosequencing
and dideoxy sequencing methods to analyze the limit of detection and assay linearity (Additional file 1: Figures S2–S5, Tables S5–S6). a To assess the
limit of detection, cell line DNA was mixed to produce samples containing differing proportions of mutant alleles. The established pyrosequencing
method allows for 2 % of EGFR exon 19 c.2235_2249del15 mutant alleles (i), 3 % of EGFR exon21 c2573 T>G mutant alleles (ii), 2 % of KRAS exon2
c.35G>T mutant alleles (iii), and 5 % of KRAS exon 2 c.38G>A mutant alleles (iiii) to be detected with confidence. The percentages on the horizontal axis
indicate the calculated percentages of mutant alleles present, while the vertical axis indicates the percentage of nucleotide. The white column
represents the percentage of detected wild-type nucleotides; the red column within the white column represents the percentage composition of the
detected mutant nucleotides. Arrows indicate the DNA dilutions in which mutations could be reliably detected above background noise. WT means
wild-type. b To assess the assay linearity of pyrosequencing, theoretical peak heights, calculated from the initial mutant allele peak percentage in
undiluted mutant cells, were correlated with actual peak heights generated for each dilution. For mutational analysis of EGFR exon 19 c.2235_2249del15
(i), KRAS exon 2 c35 G>T (iii), and c.38 G>A (iiii), Pearson’s correlation (r) = 0.99; for mutational analysis of EGFR exon 21 c.2573 T>G (ii), r = 0.96,
indicating a linear relationship. A, adenine; G, guanine; T, thymine; C, cytosine. Data are from three independent experiments
Table 2 Summary of EGFR exons 18–21 mutations in 494
NSCLC-FFPE tissues and KRAS exon 2 mutations in 1099
CRC-FFPE tissues as detected by our designed pyrosequencing
method








EGFR 19 Missense c.2239TT>CC p.L747P 1 (0.20)
19 Deletion c.2235_2249del15 p.E746_A750 53 (10.73)
c.2236_2250del15 p.E746_A750 18 (3.64)
c.2237_2251del15 p.E746_T751 2 (0.40)
c.2237_2253del17 p.E746_T751 1 (0.20)
c.2237_2255del19 p.E746_S752 1 (0.20)
c.2237_2257del21 p.E746_P753 1 (0.20)
c.2239_2248del10 p.L747_E749 2 (0.40)
c.2239_2253del15 p.L747_T751 1 (0.20)
c.2239_2256del18 p.L747_S752 2 (0.40)
c.2240_2254del15 p.L747_T751 2 (0.40)
c.2240_2257del18 p.L747_P753 5 (1.01)
c.2253_2276del24 p.S752_I759 3 (0.61)
c.2254_2277del24 p.S752_I759 1 (0.20)
21 Missense c.2573T>G p.L858R 81 (16.40)
c.2582T>A p.L861Q 2 (0.40)
Total 176 (35.63)
KRAS 2 Missense c.34G>T p.G12C 24 (2.18)
c.34G>A p.G12S 26 (2.37)
c.34G>C p.G12R 1 (0.09)
c.35G>A p.G12D 168 (15.29)
c.35G>C p.G12A 23 (2.09)






c.37G>T p.G13C 4 (0.36)
c.38G>A p.G13D 100 (9.10)
Total 437 (39.76)
EGFR epidermal growth factor receptor, KRAS V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog, NSCLC non-small cell lung cancer, CRC colorectal cancer,
FFPE formalin-fixed paraffin-embedded
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been few studies focusing on Asians, with conflicting re-
sults. Previous studies have shown that the EGFR muta-
tion rates of South Korean, Indian, and Japanese patients
were 0.96 % (1/104), 3.88 % (4/103), and 6.50 % (8/123)
[33–35], respectively. Two Chinese-based studies reported
EGFR mutation rates of 14.54 % (41/282) and 29.73 %
(11/37) [16, 17]. In the SCC cohort of this study (n = 172),
we found that the EGFR mutation rate was 19.19 %
(33/172), similar to the previously reported Chinese-based
data, implying that the EGFR mutation test for SCC needs
to be considered as a routine practice.
Our retrospective analysis of 1099 samples from Chinese
CRC patients showed that the frequency of a KRAS muta-
tion was 39.76 %, which is similar to the previously pub-
lished data from Japan, the Netherlands, Germany, and
the United States (37–43 %), but higher than those from
Thailand, India, South Korea, Oman, and Australia
(23–31 %) (Additional file 1: Table S1). Except for the
consideration of the sensitivity of the techniques used
in some studies, the variations in the frequency of the
KRAS mutation worldwide may be explained by the
patient ethnicity and geographical distribution. Studies
from western nations have reported KRAS G12D as
the most recurrent transition, followed by G12V, G12C,
G12S, and G12A [36, 37]. In our study, the corresponding
order was G12D, G12V, G12S, G12C, and G12A. Among
KRAS codon 13 mutations, G13D was the major muta-
tion, followed by G13C and G13R or G13S in western
populations [36, 37]. However, in the current study, pre-
dominantly only G13D and rarely G13C mutations were
observed, while none of the cases showed G13R. These
data suggest that there may be some racial differences in
the patterns of KRAS mutations.
In agreement with previous studies [14, 19, 38], our
results showed that KRAS mutations occurred more
frequently in females than in males. Moreover, consistent
with studies of India and Japan [13, 14], CRC patients
older than 50 years old demonstrated significantly higher
KRAS mutation rates than patients younger than 50 years
old (396/867), indicating that the older the patient, the
Table 3 Correlation of EGFR mutations with clinicopathological features of NSCLC patients
Variable Number (%) EGFR Univariate Multivariate
Mutation (%) Wild type (%) Odds ratio (95 % CI) p value Odds ratio (95 % CI) p value
Gender
Male 334 (67.61) 108 (32.34) 226 (67.66) Ref. Ref.
Female 160 (32.39) 68 (42.50) 92 (57.50) 1.55 (1.05–2.28) 0.028 0.64 (0.32–1.28) 0.209
Age
≤65 271 (54.86) 122 (45.02) 149 (54.98) 2.56 (1.73–3.78) <0.001 2.51 (1.65–3.81) <0.001
>65 223 (45.14) 54 (24.22) 169 (75.78) Ref. Ref.
Smoking history
Ever smoker 348 (70.45) 102 (29.31) 246 (70.69) Ref. Ref.
Never smoker 146 (29.55) 74 (50.68) 72 (49.32) 2.48 (1.66–3.69) <0.001 3.63 (1.83–7.19) <0.001
Never smoker
Male 21 (14.38) 11 (52.38) 10 (47.62) Ref.
Female 125 (85.62) 63 (50.40) 62 (49.60) 0.92 (0.37–2.33) 0.867
Pathologic stage
I + II 171 (34.62) 55 (32.16) 116 (67.84) Ref. Ref.
III + IV 323 (65.38) 121 (37.46) 202 (62.54) 1.26 (0.85–1.87) 0.243 1.45 (0.94– 2.24) 0.089
Pathology
Non-ADC 184 (32.75) 35 (19.02) 149 (80.98) Ref. Ref.
ADC 310 (62.75) 141 (45.48) 169 (54.52) 3.55 (2.31–5.46) <0.001 3.57 (2.28–5.61) <0.001
Male 212 (68.39) 86 (40.57) 126 (59.43) Ref.
Female 98 (31.61) 55 (56.12) 43 (43.88) 1.87 (1.15–3.04) 0.011
Never smoker ADC
Male 15 (16.13) 9 (60.00) 6 (40.00) Ref.
Female 78 (83.87) 51(65.38) 27(34.62) 1.26 (0.41–3.91) 0.69
Differentiation
Well 145 (29.35) 50 (34.48) 95 (65.52) Ref. Ref.
Moderate 249 (50.40) 92 (36.95) 157 (63.05) 1.11 (0.73–1.71) 0.623 1.14 (0.72–1.82) 0.573
Poor 97 (19.64) 34 (35.05) 63 (64.95) 1.03 (0.60–1.76) 0.927 1.10 (0.60–2.00) 0.759
EGFR epidermal growth factor receptor, NSCLC non-small cell lung cancer, ADC adenocarcinoma, CI confidence interval, Ref. reference group
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ingly, our findings demonstrate that tumors with KRAS
mutation tend to occur more frequently in ADC as com-
pared to the non-ADC subtypes, which further supports
the previous observation [13]. Other clinicopathological
features including tumor differentiation, location, and sta-
ging did not show any association with KRAS mutation in
our retrospective analysis.
Regarding the importance of EGFR and KRAS mutation
detection for the prediction and prognosis of NSCLC and
CRC, a reliable diagnostic test may affect future thera-
peutic decision-making. In this study, we demonstrated
that our designed pyrosequencing assay using a novel
nucleotide dispensation order is a reliable and accurate
technique for the detection of EGFR and KRAS hotspot
mutations from FFPE tissues. First, pyrosequencing wasestablished and validated in a set of DNA samples ob-
tained from several cell lines and mutation-positive
FFPE tumor tissues. The homozygous or heterozygous
mutations in the NSCLC (Fig. 1a) and CRC cell lines
(Fig. 1b) and mutant FFPE tissues (Fig. 1c) were accur-
ately detected with this pyrosequencing method. Next,
the sensitivity for detection of mutations by our de-
signed pyrosequencing method was sufficiently high as
it was able to detect mutations in samples containing
as few as 2 % homozygous to 5 % heterozygous mutated
alleles in a background of wild-type DNA (Fig. 2a).
Pearson’s (r) value for the four detected mutation types
statistically validated the excellent assay linearity and
reproducibility (Fig. 2b). In addition, this method was
applied to detect mutations in a large series of FFPE tis-
sues and compared with dideoxy sequencing; the results
Table 4 Correlation of KRAS mutations with clinicopathological features of CRC patients
Variables Number (%) KRAS Univariate Multivariate
Mutant (%) Wild-type (%) Odds ratio (95 % CI) p value Odds ratio (95 % CI) p value
Gender
Male 657 (59.78) 233 (35.46) 424 (64.54) Ref. Ref.
Female 442 (40.22) 204 (46.15) 238 (53.85) 1.56 (1.22–1.99) <0.001 1.64 (1.26–2.12) <0.001
Age (years)
≤50 232 (21.11) 41 (17.67) 191 (82.33) Ref. Ref.
>50 867 (78.89) 396 (45.67) 471 (54.33) 3.92 (2.72–5.63) <0.001 4.17 (2.85–6.10) <0.001
Sub-localization
Rectum 371 (33.76) 139 (37.47) 232 (62.53) Ref. Ref.
Prioximal colon 373 (33.94) 155 (41.55) 218 (58.45) 1.19 (0.88–1.59) 0.254 0.85 (0.62–1.17) 0.333
Distal colon 355 (32.30) 143 (40.28) 212 (59.72) 1.13 (0.84–1.52) 0.437 0.95 (0.69–1.31) 0.754
Dukes’ stage
A + B 614 (56.23) 244 (39.74) 370 (60.26) Ref. Ref.
C + D 478 (43.77) 192 (40.17) 286 (59.83) 1.02 (0.80–1.30) 0.886 0.99 (0.77–1.29) 0.963
Pathology
Non-ADC 54 (4.91) 10 (18.52) 44 (81.48) Ref. Ref.
ADC 1045 (95.09) 427 (40.86) 618 (59.14) 3.04 (1.51–6.11) 0.002 2.41 (1.12–5.17) 0.024
Differentiation
Well 78 (7.10) 23 (29.49) 55 (70.51) Ref. Ref.
Moderate 752 (68.43) 310 (41.22) 442 (58.78) 1.68 (1.01–2.79) 0.046 1.10 (0.62–1.96) 0.742
Poor 256 (23.29) 101 (39.45) 155 (60.55) 1.56 (0.90–2.69) 0.112 1.24 (0.66–2.30) 0.503
Unknown 13 (1.18) 3 (23.08) 10 (76.92) 0.72 (0.18–2.85) 0.637 0.53 (0.13–2.24) 0.388
KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, CRC colorectal cancer, CI confidence interval, ADC adenocarcinoma, Ref. reference group
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more mutations detected by the pyrosequencing assay
(data not shown).
Dideoxy sequencing and real-time PCR-based tech-
niques are currently the most commonly performed
methods for the detection of EGFR and KRAS mutations
in the clinic. Direct DNA sequencing has several disad-
vantages with regard to clinical application [20–22]. The
most notable one is its requirement for a DNA tem-
plate with a relatively high quality. Moreover, it has a
relatively low sensitivity, as also revealed by this study
(Additional file 1: Figures S2–S5). The real-time PCR-
based approaches, such as the amplification refractory
mutation system, peptide nucleic acid/locked nucleic
acid clamp PCR, and coamplification at lower denatur-
ation temperature PCR have been reported to be more
sensitive and detect as low as 1 % mutated alleles in
samples containing a mixture of tumor and normal cells
[16, 22]; however, the results obtained are restricted to the
screening of mutant versus wild-type tumors and lack
any further characterization. In contrast, pyrosequencing
could detect all of the mutations within the amplified re-
gion, show DNA sequences around targeted nucleo-
tide(s), and provide the quality assurance measurementthat is especially important in clinical settings [21, 39]. In
this study, our designed pyrosequencing assay using a
novel dispensation order could detect and characterize
both classical and uncommon EGFR and KRAS mutations
(Additional file 1: Figures S1, S6, and S7). In addition, most
of the types of degraded DNA extracted from NSCLC- or
CRC-FFPE tissues could be used as the pyrosequencing
template directly, without requiring further dilution or
normalization. Thus, compared with other techniques, the
pyrosequencing assay described herein is relatively simple,
reliable, and fast. Although real-time PCR-based ap-
proaches seem to be more sensitive than our modified
pyrosequencing assay, the sensitivity for the detection
of mutations by this method is sufficient as it could de-
tect mutations in samples containing as few as 2 %
mutated cancer cells (Fig. 2a).
There were some limitations in this retrospective
study. First, we had no data on survival analysis. Second,
we were unable to demonstrate the intra-patient vari-
ability of the EGFR or KRAS mutations between primary
lesions and metastatic lesions, because the tests for
EGFR and KRAS mutations were performed in either
the primary tumor or metastatic tumor sample from
each patient. Despite these limitations, using this novel
Xie et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:63 Page 11 of 12pyrosequencing method in routine clinical practice pro-
vided a large-scale screening that included unselected
Asian NSCLC and CRC patients. Furthermore, it dem-
onstrated the prevalence of EGFR and KRAS mutations
and mutation patterns in a Chinese population.
Conclusion
In summary, our findings suggest that the best clinical
independent predictive factors for targeted therapy of
Chinese NSCLC patients with EGFR inhibitors include
an ADC histology, a nonsmoking history, and a younger
age (≤65); for Chinese CRC patients, those who are fe-
male, older (>50 year old), and have ADC histology may
benefit from mAb-based molecularly targeted therapies.
Moreover, our designed pyrosequencing method using a
novel nucleotide dispensation order is a practical and re-
liable method for the detection of NSCLC EGFR and
CRC KRAS mutations in FFPE samples. The sensitivity,
accuracy, and simplicity of the procedure are suitable for
genetic testing of NSCLC and CRC patients at the clin-
ical laboratory level.
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